CCR5 blockade by MVC has been studied in GC progression in an in vivo model, with effects such as reduced the number and total volume of peritoneal and mesenteric nodules, increased median survival time, and induced extensive intratumoral necrosis in mice [16, 23], however, it has not been fully elucidated in chemoresistance models. The gene discussed is CCR5; the disease is gastric cancer.